SAB Biotherapeutics (SABS) Appoints Scott Giberson to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/6/2026
- S&P 500 struggles for direction as investors await Mideast deal; software stocks slide
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Salesforce president Srini Tallapragada steps down, becomes advisor
- Sandisk (SNDK) Tops Q4 EPS by $4.66, Offers Guidance
- EverCommerce names Alex Goor as new CEO, founder steps down
- Crude Inventory Rose 2.5 Million Barrels Last Week - EIA
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors
July 11, 2022 8:00 AM EDTSIOUX FALLS, S.D., July 11, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced the appointment of Rear Admiral (RADM), retired, Scott Giberson, a former Assistant U.S. Surgeon General and two-star admiral with the U.S. Public Health Service to SABs Board of Directors, effective July 7, 2022. RADM Giberson retired after a decorated career and 27 years of service. In 2018, the Military Officers Association of... More
